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Lassa virus, the cause of Lassa fever in humans, is en-
demic to West Africa. Treatment of Lassa fever is primarily 
supportive, although ribavirin has shown limited efficacy if 
administered early during infection. We tested favipiravir in 
Lassa virus–viremic macaques and found that 300 mg/kg 
daily for 2 weeks successfully treated infection.
Lassa virus (LASV; family Arenaviridae, genus Mam-marenavirus) is the etiologic agent of the severe 
hemorrhagic disease Lassa fever. Annually, ≈300,000 
persons become infected with LASV, 20% of which ex-
perience life-threatening clinical manifestations includ-
ing edema, hemorrhage, and multiorgan failure, resulting 
in an estimated 5,000 deaths (1). Most human infections 
are acquired from the natural rodent reservoir, the multi-
mammate rat (Mastomys natalensis). Human-to-human 
transmission, mostly nosocomial, occurs (1). LASV has a 
relatively well-defined region of endemicity exclusive to 
West Africa. Incidence of LASV infections is highest in 
Nigeria, Sierra Leone, Liberia, and Guinea, although spo-
radic cases and moderate outbreaks of Lassa fever have 
been documented in many other West Africa nations (on-
line Technical Appendix Figure 1, https://wwwnc.cdc.gov/
EID/article/24/9/18-0233-Techapp1.pdf) (2). Over several 
decades, importation of Lassa fever into Europe, Asia, and 
the Americas has increased (2).
Treatment of Lassa fever is largely supportive, although 
ribavirin is used off label, despite side effects and limited 
efficacy data (3). Recently, the antiviral favipiravir (T-705; 
6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has gained at-
tention as a broad-spectrum antiviral drug against RNA vi-
ruses (4) including LASV; initial studies using small animal 
models have been conducted (5,6). We assessed the antiviral 
efficacy of favipiravir in LASV-infected cynomolgus ma-
caques; this animal model reliably recapitulates several hall-
marks of Lassa fever infection in humans (7).
The Study
We randomly divided 8 female cynomolgus macaques 
(Macaca fascicularis) into 2 groups of 4 each (treatment 
and control) and injected each animal intramuscularly with 
a lethal dose of LASV, strain Josiah (1 × 104 50% tissue 
culture infective dose [TCID50]) (Table). Treatment began 
at 4 days postinfection (dpi), 1 day after the onset of vire-
mia (7). The initial treatment (300 mg/kg favipiravir) was 
administered intravenously; subsequent treatments (300 
mg/kg favipiravir every 24 h for 13 d) were administered 
subcutaneously. The dosage was based on the success-
ful treatment of Lassa fever in guinea pigs (5). To avoid 
the confounding effects of ribavirin, we did not give it in 
combination. LASV-infected control animals received an 
equivalent volume of vehicle by the same route and sched-
ule. Animals were assessed twice daily; physical exami-
nations, including hematologic, blood chemistry, and viro-
logic assessments, were conducted regularly.
Reduced activity and appetite, probably resulting from 
being anesthetized daily, was noted early in animals in both 
groups (Figure 1, panel A). At 6 dpi (2 d after treatment 
began), clinical scores for 3 of 4 animals in the treatment 
group plateaued and remained consistent for the remainder 
of the study. Although the score for the remaining animal 
was higher, all favipiravir-treated animals survived LASV 
challenge (p<0.01; Figure 1, panel B). In contrast, clinical 
scores for the control group increased dramatically after 8 
dpi; all control animals displayed anorexia, hunched pos-
ture, piloerection, and lethargy (Figure 1, panel A). The 
control animals reached the humane endpoint and were eu-
thanized on 10, 11, and 12 dpi (Figure 1, panel B).
Although we detected viral RNA by quantitative PCR as 
early as 3 dpi (online Technical Appendix Figure 2, panel A), 
at no time was infectious LASV isolated from blood (Figure 
1, panel C) or postmortem tissue samples (data not shown) 
from animals in the favipiravir group. However, in the 
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control animals, increased liver enzyme levels were detected 
at 6 dpi, coinciding with infectious LASV (Figure 1, pan-
els D, E). One animal in the favipiravir group demonstrated 
moderately increased levels of alanine aminotransferase and 
aspartate aminotransferase at 6–12 dpi, which resolved af-
ter treatment cessation. In the control animals, albumin and 
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Table. Study design for treatment of Lassa virus infection in cynomolgus macaques* 
Study, no. 
animals Treatment Frequency† Dose, mg/kg Loading dose, mg/kg Total daily dose, mg/kg 
Survived/total, 
no. 
First       
 4 Placebo Every 24 h Volume equivalent Volume equivalent Volume equivalent 0/4 
 4 Favipiravir Every 24 h 300 300 300 4/4 
Second       
 4 Placebo Every 8 h Volume equivalent. Volume equivalent Volume equivalent 0/4 
 4 Favipiravir Every 8 h 50 300 150 0/4 
*All animals were challenged with a previously determined lethal dose of 104 50% tissue culture infective dose of Lassa virus (strain Josiah) via 
intramuscular injection. At day 4 after infection, a time coinciding with the earliest onset of detectable viremia, treatment with placebo or drug was initiated 
by intravenous injection of the loading dose followed by daily (days 5–17) subcutaneous dosing. Animals were examined daily for clinical signs of disease, 
and samples were taken for hematologic, blood chemistry, and virologic analyses at 12 times throughout the study, beginning on the day of virus 
challenge and ending on day 56 after infection. 
†For 14 d. 
 
Figure 1. Effect of daily 
favipiravir treatments on 
morbidity and mortality rates, 
viral loads, and selected blood 
chemistry and hematology 
values during the course of the 
efficacy study in cynomolgus 
macaques challenged with 
104 TCID50 of Lassa virus. 
Groups of 4 animals each 
were given 300 mg/kg/d of 
favipiravir or placebo for 14 
consecutive days, beginning 
on day 4 postinfection. A) 
Daily clinical scores (dotted 
line indicates euthanasia 
score of 35). B) Survival 
curve (*p<0.01 compared 
with placebo-treated animals 
by the Mantel-Cox log-rank 
test). C) Viremia as assessed 
by TCID50 assay. D) Alanine 
aminotransferase levels. E) 
Aspartate aminotransferase 
levels. F) Albumin levels. G) 
Total protein levels. H) Platelet 
levels. TCID50, 50% tissue 
culture infective dose.
DISPATCHES
total protein levels decreased dramatically throughout LASV 
infection; in the favipiravir-treated animals, these levels dis-
played a more moderate decrease before returning toward 
reference levels (Figure 1, panels F, G).
Hematologic profiles were less uniform between the 
2 groups, although we observed several abnormalities pre-
viously associated with LASV infection (online Techni-
cal Appendix Figure 3). After an initial increase, platelet 
counts in the control animals consistently decreased until 
euthanasia. In 2 of the favipiravir-treated animals, a similar 
increase was noted initially; however, a marked decrease 
occurred at 6 dpi (Figure 1, panel H). Platelet levels re-
bounded by 9 dpi and continued to increase. In addition, 
all 4 favipiravir-treated animals had lipemia (>301 mg/dL) 
during the treatment phase of the study (4–18 dpi).
Histopathologic examination of livers from control 
animals demonstrated hepatitis with neutrophil invasion 
and substantial steatosis, consistent with Lassa fever in 
this model (Figure 2, panel A) (7). In contrast, livers from 
favipiravir-treated animals showed no abnormalities (Fig-
ure 2, panel B). In situ hybridization detected LASV RNA 
within hepatocytes of control animals but not treated ani-
mals (Figure 2, panels C, D).
Conclusions
Over the past 3 years, total numbers of Lassa fever cases 
and case-fatality rates among humans have increased (8). 
The current Lassa fever outbreak in Nigeria and Benin con-
tinues to show large numbers of Lassa fever cases and case-
fatality rates >30% (8), again highlighting the lack of avail-
able treatments. Furthermore, the recent person-to-person 
transmission of LASV in Germany (9) serves as a reminder 
that Lassa fever is of global health concern.
Lassa fever patients are largely managed by supportive 
care in combination with ribavirin (3). Experimental effi-
cacy of ribavirin was initially tested in a Lassa fever rhesus 
macaque model in which intramuscular injections 3 times 
daily for 14 days improved survival rates (10). In clinical 
trials in Sierra Leone, both oral and intravenous ribavirin 
increased survival rates of Lassa fever patients (11). Oral 
dosing of ribavirin has since remained the standard of 
treatment for Lassa fever, despite unproven efficacy from 
clinical studies (3,12). Moreover, side effects of ribavirin 
therapy have resulted in noncompliance (12).
The successful daily administration of favipiravir to ma-
caques at an elevated dosing regimen of 300 mg/kg/d may 
partially explain the transient thrombocytopenia, elevated 
liver enzyme levels, and lipemia found in this study. Experi-
mentally, favipiravir is a well-known broad-spectrum antivi-
ral drug with in vitro inhibitory activity against a multitude 
of RNA viruses (4). In Japan, favipiravir is approved for in-
fluenza treatment; in the United States, phase 3 clinical trials 
for the same indication have been completed (4). During the 
West Africa Ebola outbreak, favipiravir was administered to 
humans on an emergency basis under a different dosing regi-
men, but effectiveness was limited (13). We therefore de-
signed a second study that more closely followed the dosing 
in the Ebola trial (50 mg/kg every 8 h) (13). However, this 
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 Figure 2. Histologic and in situ 
hybridization analyses of livers 
from cynomolgus macaques 
infected with Lassa virus (LASV) (1 
× 104 50% tissue culture infective 
dose [TCID50]) and treated 1 time 
daily with favipiravir (treated) 
or vehicle only (control). A–B) 
Histologic analyses. A) Control, 
showing multifocal neutrophilic 
infiltrates with hepatocyte 
necrosis and degeneration 
(original magnification ×40). 
Inset shows hepatocyte necrosis 
(original magnification ×400). 
B) Treated, showing essentially 
healthy hepatic tissue (original 
magnification ×40). Inset shows 
healthy hepatic tissue (original 
magnification ×400). C–D) In situ 
hybridization analyses. C) Control, 
showing multifocal and coalescing 
viral RNA detected within 
hepatocytes (original magnification 
×100). D) Treated, showing no 
viral RNA detected (original 
magnification ×100). 
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multiple dose per day format failed to protect cynomolgus 
macaques from Lassa fever and did not alter disease progres-
sion (Table; online Technical Appendix Figure 1, panel B, 
and Figure 4, panels A–D). Of note, the high-dose favipira-
vir therapy in macaques successfully abated the pathophysi-
ologic parameters associated with LASV infection, resulting 
in survival. These results suggest that low doses of favipira-
vir have limited therapeutic effect, whereas higher doses are 
therapeutic and will improve clinical outcomes.
Favipiravir was recently administered in combination 
with ribavirin to successfully treat Lassa fever in 2 human 
patients. Although it is not possible to determine how ef-
fective favipiravir was in controlling these 2 cases, admin-
istration reduced viremia in both patients (9). Combination 
therapy with favipiravir and ribavirin in immunocompro-
mised mice with LASV infection showed efficacy with 
suboptimal doses of each drug (6). The synergistic effect 
of the 2 compounds is also supported by several other stud-
ies in rodents (14). Recently, human monoclonal antibody 
therapy protected cynomolgus macaques from LASV in-
fection (15). Combination therapy with favipiravir may be 
a future therapeutic strategy (15). On the basis of our find-
ings, improved favipiravir tolerability in humans (4), avail-
ability of an oral formulation, and its advanced preclinical 
status (according to the US Food and Drug Administra-
tion), we recommend that favipiravir enter clinical trials as 
a treatment for Lassa fever.
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